Medplus has informed the Exchange regarding 'Filing of Business Responsibility and Sustainability Report (BRSR) of the Company for the financial year 2024-25'.
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
MedPlus Health Services has filed its Business Responsibility and Sustainability Report (BRSR) for FY 2024-25 with BSE and NSE, as required under SEBI's Listing Regulations. The company reported a turnover of ₹7,220.32 million and a net worth of ₹12,403.47 million, with 98.24% of revenue from pharmaceutical retail. It operates across 14 states with 4,985 offices and 25,007 permanent employees. Key ESG highlights include the identification of material risks around data privacy, product safety, responsible marketing, and waste management, alongside opportunities in affordable healthcare access and employee wellbeing. The company is transitioning to LED lighting, exploring solar panels, phasing out plastic bags, and improving waste segregation. Customer complaints rose to 18,306 (from 15,613), and employee turnover improved to 42.09% (from 45.69%). No fatalities, bribery cases, or regulatory fines were reported during the year.
This is a routine annual ESG/sustainability disclosure required by SEBI and is part of the company's Annual Report. It provides investors with a detailed view of MedPlus's non-financial performance and ESG practices. The filing itself is unlikely to move the stock price, but investors should note the rising customer complaints, high employee turnover, and the company's ongoing sustainability initiatives as indicators of operational and governance quality.